What kind of drugs does pirfenidone (Asri) belong to and its pharmacological mechanism of action
Pirfenidone (Pirfenidone) is an oral anti-fibrotic drug mainly used to treat idiopathic pulmonary fibrosis (IPF). It is an anti-fibrotic and anti-inflammatory drug that slows down the process of fibrosis by regulating cytokines and signaling pathways, thereby delaying the decline of lung function. Unlike traditional anti-inflammatory drugs, pirfenidone not only targets inflammation, but also directly intervenes in the fibrosis mechanism of lung tissue, making it play a unique role in the treatment of chronic lung diseases.
From a pharmacological mechanism of action, pirfenidone can inhibit the transforming growth factor -β (TGF-β) signaling pathway, which is a key link in the formation of fibrosis. TGF-β will promote fibroblast proliferation and collagen deposition when overactivated in the lungs, and pirfenidone inhibits this pathway and reduces collagen production, thereby slowing down the degree of fibrosis in the lung interstitium.

In addition, pirfenidone also has certain anti-inflammatory effects. It can reduce the levels of pro-inflammatory factors such as TNF-α, IL-1β, etc., and reduce the damage of inflammatory reactions to lung tissue. By exerting both anti-fibrotic and anti-inflammatory effects, pirfenidone can clinically significantly delay the deterioration of lung function and improve patients' quality of life and exercise tolerance.
In clinical applications, pirfenidone has been proven to delay the rate of decline in lung function in patients with idiopathic pulmonary fibrosis, reduce the occurrence of acute exacerbations, and improve patient symptom management. Although drugs cannot completely reverse fibrosis, their effects on stabilizing lung function, alleviating symptoms, and improving quality of life make it an important choice for the treatment of IPF. At the same time, patients need to regularly monitor liver and kidney function during medication to ensure medication safety.
Reference materials:https://www.drugs.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)